Pharmacogenomics of adverse drug reactions: practical applications and perspectives
Pharmacogenomics of adverse drug reactions: practical applications and perspectives
复制标题
DOI：
10.2217/pgs.09.37
复制
发表时间：
2009-06-01
期刊：
影响因子：
2.1
通讯作者：
Becquemont, Laurent
中科院分区：
文献类型：
--
作者：
Becquemont, Laurent
严重药物不良反应是美国第六大死亡原因，是上市后药物停药的主要原因，在所有发达国家每年造成数十亿美元的成本。通过系统筛查药物基因组学风险因素，可以避免其中一些严重的药物不良反应。在过去的几年里，监管机构引入了药物基因组学;几种药物的标签，但尽管先验基因检测仍然被建议或推荐，但由于缺乏循证医学知识，它很少是强制性的。最近发表的药物基因组学随机、对照和正在进行的试验将逐步强制进行基因分型测试，例如HLA-B*5701（阿巴卡韦）、TPMT（6-巯基嘌呤）、CYP 2C 9加VKORC 1（华法林）和CYP 3A 5（他克莫司）。药物基因组学床上试验的平行发展肯定会在常规医疗实践中建立基于基因的处方。
Serious adverse drug reactions represent the sixth major cause of death in the USA, are the main reason for postmarketing drug withdrawal and represent billions of US dollars in costs every year in all developed countries. Some of these serious adverse drug reactions might be avoided by systematically screening for pharmacogenomic risk factors. During the last few years, regulatory agencies introduced pharmacogenomics; labels for several drugs, but although a priori genetic testing remains advised or recommended, it is seldom compulsory due to poor evidence-based medicine knowledge. Recently published pharmacogenomic randomized, controlled and ongoing trials will progressively make genotyping tests, such as those for HLA-B*5701 (abacavir), TPMT(6-mercaptopurine), CYP2C9 plus VKORC1 (warfarin) and CYP3A5 (tacrolimus), mandatory. Parallel development of pharmacogenomic bed tests will certainly establish genetically-based prescriptions in routine medical practice.